Gideon Hirschfield

List of Publications by Citations

296 papers	21,437 citations	62 h-index	142 g-index
330 ext. papers	25,950 ext. citations	9 avg, IF	6.96 L-index

#	Paper	IF	Citations
296	C-reactive protein: a critical update. *Journal of Clinical Investigation*, **2003**, 111, 1805-1812	15.9	2388
295	C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. *New England Journal of Medicine*, **2004**, 350, 1387-97	59.2	2317
294	The gut microbiota and host health: a new clinical frontier. *Gut*, **2016**, 65, 330-9	19.2	1182
293	C-reactive protein: a critical update. *Journal of Clinical Investigation*, **2003**, 111, 1805-12	15.9	1134
292	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. *New England Journal of Medicine*, **2016**, 375, 631-43	59.2	574
291	Targeting C-reactive protein for the treatment of cardiovascular disease. *Nature*, **2006**, 440, 1217-21	50.4	525
290	EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. *Journal of Hepatology*, **2017**, 67, 145-172	13.4	512
289	Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. *New England Journal of Medicine*, **2009**, 360, 2544-55	59.2	494
288	Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. *Nature Genetics*, **2011**, 43, 1131-8	36.3	415
287	Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. *Gastroenterology*, **2015**, 148, 751-61.e8	13.3	381
286	Primary sclerosing cholangitis. *Lancet, The*, **2013**, 382, 1587-99	40	370
285	Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. *Journal of Hepatology*, **2011**, 54, 374-85	13.4	356
284	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. *Nature Genetics*, **2010**, 42, 658-60	36.3	337
283	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. *Nature Genetics*, **2013**, 45, 670-5	36.3	267
282	Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. *Gastroenterology*, **2014**, 147, 1338-49.e5; quiz e15	13.3	265
281	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. *Gastroenterology*, **2015**, 149, 1804-1812.e4	13.3	235
280	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. *Gastroenterology*, **2017**, 152, 1975-1984.e8	13.3	219

279	Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. *American Journal of Gastroenterology*, **2010**, 105, 2186-94	0.7	213
278	The immunobiology and pathophysiology of primary biliary cirrhosis. *Annual Review of Pathology: Mechanisms of Disease*, **2013**, 8, 303-30	34	208
277	Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. *Gastroenterology*, **2014**, 146, 430-41.e6	13.3	193
276	Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. *Nature Genetics*, **2010**, 42, 655-7	36.3	186
275	International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. *Nature Communications*, **2015**, 6, 8019	17.4	185
274	The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. *Hepatology*, **2016**, 63, 930-50	11.2	184
273	Pathogenesis of cholestatic liver disease and therapeutic approaches. *Gastroenterology*, **2010**, 139, 1481-96	13.5	179
272	C-reactive protein and cardiovascular disease: new insights from an old molecule. *QJM - Monthly Journal of the Association of Physicians*, **2003**, 96, 793-807	2.7	173
271	Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 8309-14	11.5	172
270	The evolution of cellular deficiency in GATA2 mutation. *Blood*, **2014**, 123, 863-74	2.2	153
269	IgG4-related sclerosing disease: autoimmune pancreatitis and extrapancreatic manifestations. *Radiographics*, **2011**, 31, 1379-402	5.4	152
268	NOTCH2 mutations in Alagille syndrome. *Journal of Medical Genetics*, **2012**, 49, 138-44	5.8	152
267	Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. *Circulation*, **2005**, 111, 1530-6	16.7	150
266	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. *Nature Genetics*, **2017**, 49, 269-273	36.3	140
265	A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. *Hepatology*, **2018**, 67, 1890-1902	11.2	139
264	norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. *Journal of Hepatology*, **2017**, 67, 549-558	13.4	138
263	The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. *Gut*, **2018**, 67, 1568-1594	19.2	122
262	Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. *Human Molecular Genetics*, **2012**, 21, 5209-21	5.6	122

261	The genetics of complex cholestatic disorders. *Gastroenterology*, **2013**, 144, 1357-74	13.3	111
260	Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. *Lancet, The*, **2017**, 389, 1114-1123	49	110
259	OX40, OX40L and Autoimmunity: a Comprehensive Review. *Clinical Reviews in Allergy and Immunology*, **2016**, 50, 312-32	12.3	109
258	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. *Gut*, **2016**, 65, 321-9	19.2	107
257	PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. *Journal of Autoimmunity*, **2010**, 35, 436-42	15.5	103
256	Characterization of animal models for primary sclerosing cholangitis (PSC). *Journal of Hepatology*, **2014**, 60, 1290-303	13.4	96
255	Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. *Endoscopy*, **2017**, 49, 588-608	3.4	94
254	Novel therapeutic targets in primary biliary cirrhosis. *Nature Reviews Gastroenterology and Hepatology*, **2015**, 12, 147-58	24.2	94
253	Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. *Hepatology*, **2016**, 63, 1357-67	11.2	94
252	Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. *Journal of Hepatology*, **2014**, 60, 1249-58	13.4	92
251	The gut-adherent microbiota of PSC-IBD is distinct to that of IBD. *Gut*, **2017**, 66, 386-388	19.2	91
250	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. *Gut*, **2015**, 64, 948-56	19.2	90
249	Review article: overlap syndromes and autoimmune liver disease. *Alimentary Pharmacology and Therapeutics*, **2012**, 36, 517-33	6.1	89
248	The immunogenetics of primary biliary cirrhosis: A comprehensive review. *Journal of Autoimmunity*, **2015**, 64, 42-52	15.5	88
247	Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice. *Atherosclerosis*, **2008**, 196, 248-255	3.1	87
246	Seladelpar (MBX-8025), a selective PPAR-□agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. *The Lancet Gastroenterology and Hepatology*, **2017**, 2, 716-726	18.8	81
245	Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study. *Hepatology*, **2016**, 64, 189-99	11.2	81
244	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. *Journal of Hepatology*, **2019**, 71, 357-365	13.4	80

243	Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. *Journal of Hepatology*, **2017**,	13.4	78
242	Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. *Journal of Hepatology*, **2019**, 70, 483-493	13.4	77
241	Using GWAS to identify genetic predisposition in hepatic autoimmunity. *Journal of Autoimmunity*, **2016**, 66, 25-39	15.5	73
240	British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. *Gut*, **2019**, 68, 1356-1378	19.2	73
239	Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. *The Lancet Gastroenterology and Hepatology*, **2019**, 4, 445-453	18.8	73
238	Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. *Hepatology*, **2014**, 60, 931-40	11.2	72
237	Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. *Alimentary Pharmacology and Therapeutics*, **2016**, 43, 283-93	6.1	70
236	Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes. *Genes and Immunity*, **2012**, 13, 328-35	4.4	67
235	X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome. *Arthritis and Rheumatology*, **2016**, 68, 1290-1300	9.5	65
234	Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. *Journal of Hepatology*, **2017**, 66, 1265-1281	13.4	62
233	Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis. *Gastroenterology*, **2014**, 147, 221-232.e7	13.3	61
232	CTLA4/ICOS gene variants and haplotypes are associated with rheumatoid arthritis and primary biliary cirrhosis in the Canadian population. *Arthritis and Rheumatism*, **2009**, 60, 931-7		61
231	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. *The Lancet Gastroenterology and Hepatology*, **2018**, 3, 626-634	18.8	60
230	Cellular and Molecular Mechanisms of Autoimmune Hepatitis. *Annual Review of Pathology: Mechanisms of Disease*, **2018**, 13, 247-292	34	59
229	Primary biliary cholangitis: pathogenesis and therapeutic opportunities. *Nature Reviews Gastroenterology and Hepatology*, **2020**, 17, 93-110	24.2	58
228	The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. *Human Molecular Genetics*, **2015**, 24, 582-96	5.6	57
227	A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. *Journal of Hepatology*, **2020**, 73, 94-101	13.4	57
226	Progress in the genetics of primary biliary cirrhosis. *Seminars in Liver Disease*, **2011**, 31, 147-56	7.3	57

225	Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity. *Journal of Autoimmunity*, **2016**, 68, 98-104	15.5	53
224	Mesenchymal stromal cells and liver fibrosis: a complicated relationship. *FASEB Journal*, **2016**, 30, 3905-3928	5.48	53
223	Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival. *Gastroenterology*, **2019**, 156, 96-107.e1	13.3	52
222	The phenotypic expression of inflammatory bowel disease in patients with primary sclerosing cholangitis differs in the distribution of colitis. *Digestive Diseases and Sciences*, **2013**, 58, 2608-14	4	51
221	High-throughput T-cell receptor sequencing across chronic liver diseases reveals distinct disease-associated repertoires. *Hepatology*, **2016**, 63, 1608-19	11.2	51
220	Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. *Hepatology*, **2017**, 65, 907-919	11.2	50
219	Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 631-644	6.1	49
218	Expert clinical management of autoimmune hepatitis in the real world. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 723-732	6.1	48
217	Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis. *Liver International*, **2015**, 35, 642-51	7.9	48
216	Comparative MRI analysis of morphologic patterns of bile duct disease in IgG4-related systemic disease versus primary sclerosing cholangitis. *American Journal of Roentgenology*, **2014**, 202, 536-43	5.4	46
215	The challenges of primary biliary cholangitis: What is new and what needs to be done. *Journal of Autoimmunity*, **2019**, 105, 102328	15.5	45
214	The spectrum of sclerosing cholangitis and the relevance of IgG4 elevations in routine practice. *American Journal of Gastroenterology*, **2012**, 107, 56-63	0.7	45
213	Unmet clinical need in autoimmune liver diseases. *Journal of Hepatology*, **2015**, 62, 208-18	13.4	44
212	Mechanisms of tissue injury in autoimmune liver diseases. *Seminars in Immunopathology*, **2014**, 36, 553-68	8.2	44
211	Good maternal and fetal outcomes for pregnant women with primary biliary cirrhosis. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 1179-1185.e1	6.9	44
210	Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. *Genes and Immunity*, **2013**, 14, 179-86	4.4	44
209	Amyloidosis: new strategies for treatment. *International Journal of Biochemistry and Cell Biology*, **2003**, 35, 1608-13	5.6	44
208	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. *American Journal of Gastroenterology*, **2018**, 113, 254-264	0.7	44

207	Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists. *Hepatology*, **2016**, 63, 644-59	11.2	43
206	PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC). *PLoS ONE*, **2014**, 9, e112877	3.7	43
205	The human lymph node microenvironment unilaterally regulates T-cell activation and differentiation. *PLoS Biology*, **2018**, 16, e2005046	9.7	43
204	Low-dose interleukin-2 promotes STAT-5 phosphorylation, T survival and CTLA-4-dependent function in autoimmune liver diseases. *Clinical and Experimental Immunology*, **2017**, 188, 394-411	6.2	42
203	Obeticholic acid for the treatment of primary biliary cirrhosis. *Expert Review of Clinical Pharmacology*, **2016**, 9, 13-26	3.8	42
202	Autoantibodies and liver disease: uses and abuses. *Canadian Journal of Gastroenterology & Hepatology*, **2010**, 24, 225-31		42
201	Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy. *Scandinavian Journal of Gastroenterology*, **2016**, 51, 329-36	2.4	41
200	Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome. *Clinical Immunology*, **2016**, 168, 25-29	9	41
199	The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis. *Alimentary Pharmacology and Therapeutics*, **2016**, 44, 1039-1050	6.1	41
198	Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age. *Gastroenterology*, **2020**, 159, 915-928	13.3	37
197	A Pilot Integrative Analysis of Colonic Gene Expression, Gut Microbiota, and Immune Infiltration in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Association of Disease With Bile Acid Pathways. *Journal of Crohn's and Colitis*, **2020**, 14, 935-947	1.5	36
196	Identifying opportunities to improve management of autoimmune hepatitis: evaluation of drug adherence and psychosocial factors. *Journal of Hepatology*, **2012**, 57, 1299-304	13.4	36
195	The specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice. *Hepatology*, **2010**, 52, 562-70	11.2	36
194	Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner. *Gut*, **2018**, 67, 1135-1145	19.2	35
193	Carriage of a tumor necrosis factor polymorphism amplifies the cytotoxic T-lymphocyte antigen 4 attributed risk of primary biliary cirrhosis: evidence for a gene-gene interaction. *Hepatology*, **2010**, 52, 223-9	11.2	35
192	Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. *Hepatology*, **2018**, 67, 1920-1930	11.2	35
191	A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2015**, 41, 980-90	6.1	34
190	Treatment of autoimmune liver disease: current and future therapeutic options. *Therapeutic Advances in Chronic Disease*, **2013**, 4, 119-41	4.9	34

189	Gilbert's syndrome: an overview for clinical biochemists. *Annals of Clinical Biochemistry*, **2006**, 43, 340-3	2.2	34
188	Primary biliary cholangitis. *Lancet, The*, **2020**, 396, 1915-1926	40	33
187	Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting. *American Heart Journal*, **2004**, 147, 1071-7	4.9	32
186	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. *American Journal of Gastroenterology*, **2020**, 115, 1066-1074	0.7	31
185	Human C-reactive protein does not protect against acute lipopolysaccharide challenge in mice. *Journal of Immunology*, **2003**, 171, 6046-51	5.3	31
184	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. *Gut*, **2021**,	19.2	31
183	Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study. *Scientific Reports*, **2018**, 8, 9189	4.9	31
182	A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. *Hepatology Communications*, **2019**, 3, 365-381	6	30
181	Biliary atresia and survival into adulthood without transplantation: a collaborative multicentre clinic review. *Liver International*, **2012**, 32, 510-8	7.9	30
180	Amyloidosis: a clinico-pathophysiological synopsis. *Seminars in Cell and Developmental Biology*, **2004** , 15, 39-44	7.5	30
179	Factors that Influence Health-Related Quality of Life in Patients with Primary Sclerosing Cholangitis. *Digestive Diseases and Sciences*, **2016**, 61, 1692-9	4	29
178	Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. *Alimentary Pharmacology and Therapeutics*, **2019**, 50, 1127-1136	6.1	29
177	Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögren's Syndrome. *Arthritis and Rheumatology*, **2017**, 69, 2187-2192	9.5	29
176	Phenotyping and auto-antibody production by liver-infiltrating B cells in primary sclerosing cholangitis and primary biliary cholangitis. *Journal of Autoimmunity*, **2017**, 77, 45-54	15.5	29
175	Insights into the management of Wilson's disease. *Therapeutic Advances in Gastroenterology*, **2017**, 10, 889-905	4.7	29
174	A validated clinical tool for the prediction of varices in PBC: the Newcastle Varices in PBC Score. *Journal of Hepatology*, **2013**, 59, 327-35	13.4	28
173	Diagnosis of primary biliary cirrhosis. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2011**, 25, 701-12	2.5	28
172	Recipient HLA-DR3, tumour necrosis factor-alpha promoter allele-2 (tumour necrosis factor-2) and cytomegalovirus infection are interrelated risk factors for chronic rejection of liver grafts. *Journal of Hepatology*, **2001**, 34, 711-5	13.4	28

171	Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System. *Hepatology*, **2019**, 69, 2120-2135	11.2	28
170	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. *Gut*, **2018**, 67, 1517-1524	19.2	28
169	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 2076-2084.e2	6.9	27
168	Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 278-287.e7	6.9	27
167	Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease. *Journal of Hepatology*, **2017**, 66, 116-122	13.4	27
166	Autoimmune hepatitis: an approach to disease understanding and management. *British Medical Bulletin*, **2015**, 114, 181-91	5.4	26
165	Increased sensitivity of Treg cells from patients with PBC to low dose IL-12 drives their differentiation into IFN-β secreting cells. *Journal of Autoimmunity*, **2018**, 94, 143-155	15.5	25
164	Improvement of ischemic cholangiopathy in three patients with hereditary hemorrhagic telangiectasia following treatment with bevacizumab. *Journal of Hepatology*, **2013**, 59, 186-9	13.4	25
163	Patients with autoimmune hepatitis who have antimitochondrial antibodies need long-term follow-up to detect late development of primary biliary cirrhosis. *Clinical Gastroenterology and Hepatology*, **2012**, 10, 682-4	6.9	25
162	Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis. *Journal of Hepatology*, **2017**, 67, 957-965	13.4	24
161	Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. *Hepatology*, **2012**, 55, 1495-506	11.2	24
160	Prevalence and risk factors for liver biochemical abnormalities in Canadian patients with systemic lupus erythematosus. *Journal of Rheumatology*, **2012**, 39, 254-61	4.1	24
159	Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group. *JHEP Reports*, **2019**, 1, 437-445	10.3	24
158	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 179-187.e6	6.9	24
157	Grand round: Autoimmune hepatitis. *Journal of Hepatology*, **2019**, 70, 773-784	13.4	23
156	The Pathogenesis of Primary Biliary Cholangitis: A Comprehensive Review. *Seminars in Liver Disease*, **2020**, 40, 34-48	7.3	23
155	Primary biliary cirrhosis: one disease with many faces. *Israel Medical Association Journal*, **2011**, 13, 55-9	0.9	23
154	A liver mass post-Fontan operation. *QJM - Monthly Journal of the Association of Physicians*, **2014**, 107, 571-2	2.7	22

153	Antimitochondrial antibody-negative primary biliary cirrhosis. *Clinics in Liver Disease*, **2008**, 12, 323-31; viii-ix	4.6	22
152	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. *Journal of Hepatology*, **2020**, 73, 559-565	13.4	21
151	Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis. *Hepatology Communications*, **2018**, 2, 421-436	6	21
150	BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial. *BMC Gastroenterology*, **2016**, 16, 71	3	21
149	The Pathogenesis of Autoimmune Liver Disease. *Digestive Diseases*, **2016**, 34, 327-33	3.2	21
148	Liver homing of clinical grade Tregs after therapeutic infusion in patients with autoimmune hepatitis. *JHEP Reports*, **2019**, 1, 286-296	10.3	20
147	Genetics in PBC: what do the "risk genes" teach us?. *Clinical Reviews in Allergy and Immunology*, **2015**, 48, 176-81	12.3	20
146	Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom. *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 951-960	6.1	20
145	Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. *Digestive Diseases*, **2017**, 35, 267-274	3.2	19
144	The impact of ileal pouch-anal anastomosis on graft survival following liver transplantation for primary sclerosing cholangitis. *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 322-332	6.1	19
143	Proximity to transplant center and outcome among liver transplant patients. *American Journal of Transplantation*, **2019**, 19, 208-220	8.7	19
142	Frequency and significance of IgG4 immunohistochemical staining in liver explants from patients with primary sclerosing cholangitis. *International Journal of Experimental Pathology*, **2014**, 95, 209-15	2.8	19
141	Fatal reactivation of hepatitis B after chemotherapy for lymphoma. *BMJ, The*, **2008**, 337, a423	5.9	19
140	IgG4 related disease - a retrospective descriptive study highlighting Canadian experiences in diagnosis and management. *BMC Gastroenterology*, **2013**, 13, 168	3	18
139	Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol. *BMJ Open*, **2017**, 7, e015081	3	18
138	Cholestasis and cholestatic syndromes. *Current Opinion in Gastroenterology*, **2009**, 25, 175-9	3	18
137	The Immunogenetics of Autoimmune Cholestasis. *Clinics in Liver Disease*, **2016**, 20, 15-31	4.6	17
136	Hepatocellular carcinoma for the non-specialist. *BMJ, The*, **2009**, 339, b5039	5.9	17

135	A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. *Journal of Hepatology*, **2021**, 74, 321-329	13.4	17
134	Primary biliary cholangitis in 2016: High-definition PBC: biology, models and therapeutic advances. *Nature Reviews Gastroenterology and Hepatology*, **2017**, 14, 76-78	24.2	16
133	Pruritus Is Common and Undertreated in Patients With Primary Biliary Cholangitis in the United Kingdom. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 1379-1387.e3	6.9	16
132	Genetic determinants of cholestasis. *Clinics in Liver Disease*, **2013**, 17, 147-59	4.6	16
131	A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. *Journal of Hepatology*, **2021**, 74, 1344-1354	13.4	16
130	Single-gene association between GATA-2 and autoimmune hepatitis: A novel genetic insight highlighting immunologic pathways to disease. *Journal of Hepatology*, **2016**, 64, 1190-1193	13.4	15
129	New Approaches to Investigate Drug-Induced Hypersensitivity. *Chemical Research in Toxicology*, **2017**, 30, 239-259	4	15
128	A comparison of depression screening instruments in hepatitis C and the impact of depression on somatic symptoms. *Psychosomatics*, **2011**, 52, 433-40	2.6	15
127	New insights into autoimmune liver diseases. *Hepatology Research*, **2008**, 38, 745-61	5.1	15
126	Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. *Hepatology*, **2020**, 72, 1253-1266	11.2	15
125	Simple Magnetic Resonance Scores Associate With Outcomes of Patients With Primary Sclerosing Cholangitis. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 2785-2792.e3	6.9	14
124	Adult liver transplantation: what non-specialists need to know. *BMJ, The*, **2009**, 338, b1670	5.9	14
123	Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus. *Liver International*, **2019**, 39, 967-975	7.9	13
122	Preventative hepatology: minimising symptoms and optimising care. *Liver International*, **2008**, 28, 922-34	7.9	13
121	A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis. *Scientific Reports*, **2020**, 10, 15308	4.9	13
120	Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. *Gut*, **2020**, 69, 1502-1509	19.2	13
119	Pathophysiology of primary biliary cholangitis. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2018**, 34-35, 17-25	2.5	13
118	Real-World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis. *Hepatology Communications*, **2020**, 4, 1332-1345	6	12

117	The Pathophysiology of Cholestasis and Its Relevance to Clinical Practice. *Clinical Liver Disease*, **2020**, 15, 110-114	2.2	12
116	Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 1213-1219	6.1	12
115	Immunogenetics in primary sclerosing cholangitis. *Current Opinion in Gastroenterology*, **2017**, 33, 93-98	3	12
114	Wilson disease: Canadian perspectives on presentation and outcomes from an adult ambulatory setting. *Canadian Journal of Gastroenterology & Hepatology*, **2012**, 26, 333-9		12
113	An overview of the diagnosis and management of immunoglobulin G4-related disease. *Cmaj*, **2016**, 188, 953-961	3.5	11
112	Deciphering the biology of IgG4-related disease: specific antigens and disease?. *Gut*, **2018**, 67, 602-605	19.2	11
111	Transient development of anti-mitochondrial antibodies accompanies autoimmune hepatitis-sclerosing cholangitis overlap. *Gut*, **2009**, 58, 152-3	19.2	11
110	Autoimmune liver disease for the non-specialist. *BMJ, The*, **2009**, 339, b3305	5.9	11
109	Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases. *JHEP Reports*, **2021**, 3, 100255	10.3	11
108	Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis. *Journal of Hepatology*, **2021**, 75, 634-646	13.4	11
107	Management of primary sclerosing cholangitis: conventions and controversies. *Canadian Journal of Gastroenterology & Hepatology*, **2012**, 26, 261-8		10
106	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 684-692.e6	6.9	10
105	Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis. *JHEP Reports*, **2021**, 3, 100217	10.3	10
104	Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis. *Frontiers in Endocrinology*, **2020**, 11, 575843	5.7	10
103	Managing hepatitis C virus infection. *BMJ, The*, **2009**, 338, b2366	5.9	9
102	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. *Gastroenterology*, **2021**, 160, 2483-2495.e26	13.3	9
101	Cirrhosis-associated immune dysfunction: Novel insights in impaired adaptive immunity. *EBioMedicine*, **2019**, 50, 3-4	8.8	9
100	The Complementary Value of Magnetic Resonance Imaging and Vibration-Controlled Transient Elastography for Risk Stratification in Primary Sclerosing Cholangitis. *American Journal of Gastroenterology*, **2019**, 114, 1878-1885	0.7	9

99	Primary biliary cirrhosis: Renaming primary biliary cirrhosis-clarity or confusion?. *Nature Reviews Gastroenterology and Hepatology*, **2015**, 12, 678-9	24.2	8
98	A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist. *Gastroenterology and Hepatology*, **2019**, 15, 145-154	0.7	8
97	Review article: pathophysiology and management of primary biliary cholangitis. *Alimentary Pharmacology and Therapeutics*, **2020**, 52, 1150-1164	6.1	8
96	Intrahepatic macrophage populations in the pathophysiology of primary sclerosing cholangitis. *JHEP Reports*, **2019**, 1, 369-376	10.3	8
95	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. *Journal of Hepatology*, **2021**, 75, 572-581	13.4	8
94	Making the most of new genetic risk factors - genetic and epigenetic fine mapping of causal autoimmune disease variants. *Clinics and Research in Hepatology and Gastroenterology*, **2015**, 39, 408-11	2.4	7
93	Post-prophylaxis Toxoplasma chorioretinitis following donor-recipient mismatched liver transplantation. *Transplant Infectious Disease*, **2016**, 18, 805-808	2.7	7
92	Overlap syndrome: A real syndrome?. *Clinical Liver Disease*, **2014**, 3, 43-47	2.2	7
91	Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps. *Liver International*, **2020**, 40, 382-392	7.9	7
90	The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis. *Hepatology* , **2021**, 74, 3269-3283	11.2	7
89	Recent advances in clinical practice: epidemiology of autoimmune liver diseases. *Gut*, **2021**, 70, 1989-2003	19.2	7
88	The Epidemiology of UK Autoimmune Liver Disease Varies With Geographic Latitude. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 2587-2596	6.9	7
87	Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. *Liver International*, **2021**,	7.9	7
86	Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis. *Liver International*, **2020**, 40, 1121-1129	7.9	6
85	Letter: histology is relevant for risk stratification in primary biliary cholangitis. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 192-193	6.1	6
84	The role of attachment style and depression in patients with hepatitis C. *Journal of Clinical Psychology in Medical Settings*, **2013**, 20, 227-33	2	6
83	Should we screen for cirrhosis?. *BMJ, The*, **2017**, 358, j3233	5.9	6
82	Aspects of the Pathophysiology of Primary Biliary Cirrhosis. *Digestive Diseases*, **2015**, 33 Suppl 2, 102-8	3.2	6

81	Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1248-1257	6.9	6
80	Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis. *JHEP Reports*, **2021**, 3, 100191	10.3	6
79	Multiparametric Magnetic Resonance Imaging, Autoimmune Hepatitis, and Prediction of Disease Activity. *Hepatology Communications*, **2021**, 5, 1009-1020	6	6
78	Gut and Liver B Cells of Common Clonal Origin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease. *Hepatology Communications*, **2018**, 2, 956-967	6	6
77	Risk stratification in primary sclerosing cholangitis: comparison of biliary stricture severity on MRCP versus liver stiffness by MR elastography and vibration-controlled transient elastography. *European Radiology*, **2020**, 30, 3735-3747	8	5
76	Primary sclerosing cholangitis and the management of uncertainty and complexity. *Frontline Gastroenterology*, **2017**, 8, 260-266	2.6	5
75	Current status of therapy in autoimmune liver disease. *Therapeutic Advances in Gastroenterology*, **2009**, 2, 11-28	4.7	5
74	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1688-1697.e14	6.9	5
73	Guideline review: British Society of Gastroenterology/UK-PBC Primary Biliary Cholangitis treatment and management guidelines. *Frontline Gastroenterology*, **2019**, 10, 316-319	2.6	5
72	Liver disease in the UK. *Lancet, The*, **2015**, 385, 503	40	4
71	Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab. *Frontline Gastroenterology*, **2016**, 7, 271-274	2.6	4
70	Genetic association studies and the risk factors for developing the "Immuno-bile-logic" disease primary biliary cholangitis. *Hepatology*, **2018**, 67, 1620-1622	11.2	3
69	Autoimmune hepatitis and complexities in management. *Frontline Gastroenterology*, **2019**, 10, 77-87	2.6	3
68	Genetic variation at the CD28 locus and its impact on expansion of pro-inflammatory CD28 negative T cells in healthy individuals. *Scientific Reports*, **2017**, 7, 7652	4.9	3
67	HLA haplotypes in primary sclerosing cholangitis patients of admixed and non-European ancestry. *Hla*, **2017**, 90, 228-233	1.9	3
66	Genetics of autoimmune liver disease: a brief summary for clinicians. *Digestive Diseases*, **2014**, 32, e1-6	3.2	3
65	Genetics of Primary Biliary Cirrhosis **2013**,		3
64	Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United Kingdom. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 768-776.e10	6.9	3

63	Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis. *Liver International*, **2021**, 41, 535-544	7.9	3
62	A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.. *Journal of Hepatology*, **2022**,	13.4	3
61	Portal hypertension in polycystic liver disease patients does not affect wait-list or immediate post-liver transplantation outcomes. *World Journal of Gastroenterology*, **2016**, 22, 9966-9973	5.6	2
60	A consensus integrated care pathway for patients with primary biliary cholangitis: a guideline-based approach to clinical care of patients. *Expert Review of Gastroenterology and Hepatology*, **2021**, 15, 929-939	4.2	2
59	Serum alkaline phosphatase in multidrug resistance 2 (Mdr2(-/-)) knockout mice is strain specific. *Hepatology*, **2016**, 63, 346	11.2	2
58	Primary Sclerosing Cholangitis With Features of Autoimmune Hepatitis: Exploring the Global Variation in Management. *Hepatology Communications*, **2020**, 4, 399-408	6	1
57	Work in Progress: Drugs in Development. *Clinics in Liver Disease*, **2018**, 22, 501-515	4.6	1
56	Autoimmune Hepatitis and Overlap Syndromes **2011**, 452-477		1
55	Navigating the road to personalized medicine: can we believe?. *Cmaj*, **2010**, 182, 651-2	3.5	1
54	Primary biliary cirrhosis: the future. *Clinics in Liver Disease*, **2008**, 12, 473-9; xi	4.6	1
53	Therapeutic Inhibition of C-Reactive Protein-Novel Drugs, Novel Mechanisms. *Clinical Science*, **2003**, 104, 65P-66P		1
52	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation.. *Journal of Hepatology*, **2022**,	13.4	1
51	Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool. *European Journal of Gastroenterology and Hepatology*, **2020**, 33,	2.2	1
50	The 6 CBs of primary sclerosing cholangitis. *Journal of Hepatology*, **2020**, 73, 1255-1256	13.4	1
49	A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis. *American Journal of Gastroenterology*, **2021**, 116, 1514-1522	0.7	1
48	Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liver-Related Mortality Is Higher in Males?. *Hepatology*, **2021**, 74, 2307	11.2	1
47	Autoimmune liver disease: evaluating overlapping and cross-over presentations-a case-based discussion. *Frontline Gastroenterology*, **2016**, 7, 240-245	2.6	1
46	Barriers to implementation of stratified care in primary biliary cholangitis: a scoping exercise. *BMJ Open Gastroenterology*, **2019**, 6, e000226	3.9	1

45	Esophageal Stenting as Bridge Therapy to Direct Intrahepatic Portocaval Shunt for Refractory Variceal Bleeding. *Hepatology*, **2021**, 73, 1618-1620	11.2	1
44	CD80 on Human T Cells Is Associated With FoxP3 Expression and Supports Treg Homeostasis. *Frontiers in Immunology*, **2020**, 11, 577655	8.4	1
43	The evolving potential of precision medicine in the management of autoimmune liver disease **2021**, 135-167		1
42	Evaluation of quantitative MRCP (MRCP+) for risk stratification of primary sclerosing cholangitis: comparison with morphological MRCP, MR elastography, and biochemical risk scores. *European Radiology*, **2022**, 32, 67-77	8	1
41	The Impact of Primary Liver Disease and Social Determinants in a Mixed Donor Liver Transplant Program: A Single-Center Analysis. *Liver Transplantation*, **2021**, 27, 1733-1746	4.5	1
40	The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study. *EBioMedicine*, **2022**, 80, 104068	8.8	1
39	Liver disease in the young adult: the challenges and rewards. *The Lancet Gastroenterology and Hepatology*, **2019**, 4, 248-254	18.8	0
38	Primary Biliary Cholangitis **2020**, 123-141		0
37	Elevated Serum Aminotransferases.. *JAMA - Journal of the American Medical Association*, **2022**, 327, 580-581	37.4	0
36	Wilson Disease: When Should you Think of Wilson Disease?352-366		0
35	Internal medicine hospitalisations and liver disease: a comparative disease burden analysis of a multicentre cohort. *Alimentary Pharmacology and Therapeutics*, **2021**, 54, 689-698	6.1	0
34	Primary Biliary Cholangitis (Formerly Primary Biliary Cirrhosis) **2019**, 574-591		0
33	Sex Disparity in Liver Transplant and Access to Living Donation. *JAMA Surgery*, **2021**, 156, 1010-1017	5.4	0
32	In Vitro and Ex Vivo Models to Study T Cell Migration Through the Human Liver Parenchyma. *Methods in Molecular Biology*, **2017**, 1591, 195-214	1.4	
31	Recurrent Autoimmune Liver Disease and Its Impact on Clinical Practice **2020**, 233-245		
30	The Role of Extrahepatic Autoimmunity in Autoimmune Liver Disease **2020**, 277-288		
29	Symptoms, Chronic Disease, and Patient Management **2020**, 289-300		
28	Environmental Exposure and Risk in Autoimmune Liver Diseases **2020**, 83-102		

27	Recurrent Autoimmune Liver Disease and its Scientific Significance **2020**, 247-261	
26	Making Sense of Overlap and Crossover Syndromes **2020**, 263-275	
25	Genetics and Risk of Autoimmune Liver Diseases **2020**, 47-64	
24	Reply. *Gastroenterology*, **2016**, 150, 1689-1690	13.3
23	Autoimmune Hepatitis and Overlap Syndromes **2018**, 355-379	
22	Primary Biliary Cholangitis **2018**, 217-232	
21	Secondary Sclerosing Cholangitis **2013**, 123-133	
20	Reply: To PMID 25160979. *Gastroenterology*, **2015**, 148, 860-1	13.3
19	Reply: To PMID 25500425. *Gastroenterology*, **2015**, 149, 508-9	13.3
18	Reply to: "AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis". *Journal of Hepatology*, **2014**, 61, 1445-6	13.4
17	Overlap Syndromes **2012**, 782-789	
16	Metagenomics and autoimmune liver disease: searching for the unknown. *Liver International*, **2009**, 29, 319-20	7.9
15	The genetic study of primary biliary cirrhosis: great hope, some caution. *Current Gastroenterology Reports*, **2008**, 10, 187-9	5
14	Evaluation of Bacterial Dna Probe Analysis in Valvular Heart Disease. *Clinical Science*, **2003**, 104, 4P-4P	
13	P066 Lower serum concentration of sulfated bile acids is associated with Primary Sclerosing Cholangitis Inflammatory Bowel Disease comorbidity and advanced liver fibrosis. *Journal of Crohn's and Colitis*, **2022**, 16, i173-i174	1.5
12	Primary Biliary Cholangitis: Clinical Insights Into Diagnosis and Staging. *Gastroenterology and Hepatology*, **2021**, 17, 2-5	0.7
11	The Evolving Use of Biochemical Markers in the Management of Primary Biliary Cholangitis: Discussion. *Gastroenterology and Hepatology*, **2021**, 17, 14-17	0.7
10	Genetics of Primary Sclerosing Cholangitis **2017**, 99-110	

9	Autoimmune Hepatitis and Crossover Syndromes. *In Clinical Practice*, **2017**, 203-226	0
8	A massive haematemesis. *BMJ, The*, **2010**, 340, b5534	5.9
7	Autoimmune Hepatitis in Adults and Children281-296	
6	Chronic Cholestatic Liver Disease and its Management in Adults and Children297-314	
5	The Diagnosis and Classification of Immune-Mediated Biliary Diseases **2014**, 111-122	
4	Diagnosis and Management of Recurrent Autoimmune Liver Disease **2021**, 424-437	
3	Proceeding: Single Topic Conference in Autoimmune Liver Disease from the Canadian Association for the Study of the Liver. *Canadian Liver Journal*,e20210006	0.3
2	Response to "Is the hub-and-spoke model of care delivery a possible answer to geographical variation in liver transplant outcomes?". *American Journal of Transplantation*, **2019**, 19, 1248-1249	8.7
1	Monoclonal antibody BTT1023 targeting vascular adhesion protein 1 for treating primary sclerosing cholangitis: BUTEO single-arm Phase II trial. *Efficacy and Mechanism Evaluation*, **2022**, 9, 1-54	1.7